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High Intensity Focused Ultrasound in the treatment of breast Fibroadenomata 1 
(HIFU-F trial) 2 
Background: High intensity focused ultrasound (HIFU) is a non-invasive ablative 3 
technique utilising the application of high frequency ultrasound (US) pressure 4 
waves to cause tissue necrosis. This emerging technology is currently limited by 5 
prolonged treatment times. The aim of the HIFU-F trial was to perform 6 
circumferential HIFU treatment as a means of shortening treatment times. 7 
Methods: A prospective trial was set up to treat 50 consecutive patients ≥18 years 8 
of age. Eligible patients possessed symptomatic fibroadenomata, visible on US. 9 
Patients ≥25 years of age required histological confirmation of the diagnosis. 10 
Primary outcome measures were reduction in treatment time, reduction in volume 11 
on US after 12 months and complication rates. 12 
Results: HIFU treatment was performed in 51 patients (53 treatments) with a mean 13 
age of 29.8 years (SD 7.2 years) and diameter of 2.6 cm (SD 1.4 cm). 14 
Circumferential ablation reduced treatment times by an estimated 19.9 minutes (SD 15 
25.1 minutes), which is a 29.4% (SD 15.2%) reduction compared to whole lesion 16 
ablation. Volume reduction of 43.2% (SD 35.4%; p<0.005, paired t-test) was 17 
observed on US at 12 months post-treatment. Local complications completely 18 
resolved at one month apart from skin hyper-pigmentation, which persisted in nine 19 
cases at three months, six cases at six months and six at 12 months.  20 
Conclusion: Circumferential HIFU treatment for breast fibroadenomata is feasible 21 
to reduce both lesion size and treatment time. HIFU is a non-invasive alternative 22 
technique for the treatment of breast fibroadenomata and required further 23 
evaluation.  24 
ISRCTN registration: 76622747 25 
Keywords: High intensity focused ultrasound (HIFU); breast fibroadenomata 26 
(FAD); ablative technique; ultrasound; minimally invasive surgery. 27 
  28 
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Introduction 1 
Fibroadenomata represent the most common benign breast lumps in women [1, 2]. 2 
Fibroadenomata are diagnosed clinically as a palpable lump or incidentally during breast 3 
imaging [2, 3]. The diagnosis is based upon triple assessment (clinical examination, 4 
ultrasound (US) and a core needle biopsy (CNB)) [1, 2, 3]. Patients with asymptomatic, 5 
biopsy-proven breast fibroadenomata are generally managed by reassurance and no 6 
follow-up is deemed necessary. Symptomatic or rapidly growing lesions are suitable for 7 
excision, either surgically or radiologically (e.g. by vacuum-assisted mammotomy) 8 
although these techniques have limitations associated with an invasive procedure [1, 2, 9 
3].  10 
High intensity focused ultrasound (HIFU) is a non-invasive ablative technique. 11 
During HIFU treatment, an US beam generated by a transducer propagates through soft 12 
tissue as a high-frequency pressure wave [4, 5]. The beam is focused onto the target tissue 13 
and the energy from the beam elevates the temperature of the targeted area to about 60 to 14 
95 degrees Celsius within seconds, leading to localised protein denaturation and 15 
coagulative necrosis - sparing the surrounding tissues from thermal damage [4, 5, 6]. 16 
HIFU provides a completely non-invasive treatment, avoiding the potential complications 17 
associated with general anaesthesia and surgical excision [7].  18 
Data from systematic reviews [8, 9] suggest that pilot studies of the treatment of 19 
breast cancer possess prolonged treatment times – of up to three hours – as a significant 20 
disadvantage with the current HIFU technique. The aim of the HIFU-F trial was to 21 
perform circumferential HIFU treatment in order to isolate the fibroadenoma from its 22 
blood supply, resulting in necrosis of the fibroadenoma and a reduced treatment time. In 23 
a recently published article [10], a protocol planned analysis of the first 20 patients 24 
included in this trial were compared to a control group of 20 patients who underwent only 25 
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an US scan at six months after their initial diagnosis to determine the natural change in 1 
fibroadenoma volume. The study demonstrated that circumferential ablation reduced the 2 
mean treatment time by 37.5% (SD 20.1%) compared to whole lesion ablation. In 3 
addition, a significant mean reduction in fibroadenoma volume of 43.5% (SD 38.8%; 4 
p=0.016, paired t-test) in the HIFU group compared to 4.6% (SD 46.0%; p=0.530) in the 5 
control group was demonstrated on US after six months. This mean reduction in volume 6 
between the two groups was statistically significant in favour of the HIFU group 7 
(p=0.002, grouped t-test). This article reports on HIFU treatment of all 51 patients who 8 
participated in the HIFU-F trial with a minimum follow-up of 12 months. 9 
Materials and Methods 10 
A prospective trial was set up to treat 50 consecutive patients with circumferential HIFU. 11 
Written informed consent was obtained from all patients prior to inclusion. This study 12 
was approved by the National Research Ethics Committee (13/LO/1221).  13 
Patient selection 14 
As described in the article by Peek et al. [10], patients were eligible for the HIFU-F trial 15 
if they were at least 18 years of age and had been referred to the one-stop Breast Clinic 16 
at Guy’s Hospital with a symptomatic fibroadenomata – defined as either a palpable 17 
lesion with or without pain developing from this lesion – which was visible on US. 18 
Patients of 25 years of age or older required confirmation of the diagnosis by US guided 19 
core needle biopsy, as per local Unit protocol. Patients were excluded if they had a 20 
fibroadenoma of less than 1 cm, had previous breast implants, were pregnant or lactating, 21 
had received any laser or radiation therapy to the ipsilateral breast, if epithelial atypia was 22 
seen on histopathology or if there was any suspicion of a phyllodes tumour. No other 23 
exclusions were applied.  24 
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A control group including 20 patients were consecutively recruited, without matching 1 
with the HIFU group, to determine the natural course in volume change of their 2 
fibroadenoma as assessed by US, six months after initial presentation. Patients were 3 
recruited using the same inclusion and exclusion criteria as the HIFU treatment group, 4 
demonstrating a definite treatment response in the HIFU group  [10]. 5 
All eligible patients were identified: (1) at the multi-disciplinary meeting (MDM), 6 
(2) as scheduled for surgical excision of a fibroadenoma or (3) as referred to the breast 7 
clinic with a symptomatic breast lump requesting treatment. All eligible patients were 8 
approached and received a patient information sheet if interested in participating in the 9 
HIFU-F trial.  10 
Primary outcome measures were the change in treatment time compared to whole 11 
lesion ablation (estimation based on the computerised treatment plan) and the volume 12 
reduction on US after 12 months. Secondary outcomes were the complication rate and 13 
patient recorded outcome measures (palpability of the lump and pain pre- and post-14 
treatment measured with visual analog scale (VAS)).  15 
HIFU treatment 16 
Patients were treated using the US-guided-Echopulse device (Theraclion Ltd, Malakoff, 17 
France), which is CE marked for the treatment of breast fibroadenomata and thyroid 18 
nodules. The device contains a cooling and coupling disposable unit to cool the skin 19 
during treatment. Treatment was performed under real-time US guidance using a 7.5 to 20 
12 MHz diagnostic transducer and a 3.0 MHz therapeutic transducer with a central hole 21 
measuring 1.1 cm for the coaxial imaging transducer. Oval tissue volumes of 22 
approximately 0.9 cm in length and 0.2 cm in height and width were ablated. No updates 23 
in software or hardware were used during this study. 24 
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All patients received treatment as a day-case procedure using local anaesthesia 1 
(1.0% Lidocaiïne with adrenaline with or without 0.25 to 0.5% Bupivacaiïne, ratio 1:1). 2 
In cases where the fibroadenoma was located close (<0.5 cm) to the skin or pectoralis 3 
major muscle, local anaesthesia was injected between the fibroadenoma and the skin or 4 
muscle. Depending on the size of the breast and the position of the fibroadenoma, the 5 
patient was placed in either a supine or lateral position and the breast was fixed using an 6 
immobilisation system. Retro-areolar FAD were treated with the patient placed in a lateral 7 
position. After an US scan with a handheld probe was performed to locate the 8 
fibroadenoma, the device head was positioned on top of the fibroadenoma to outline the 9 
fibroadenoma and the skin in the radial and anti-radial view. For every radial slice, all 10 
treatment pulses were visualised and adjusted if required. The procedure started with a 11 
single pulse in the centre of the fibroadenoma in order to determine the correct energy 12 
level, identified by a hyper-echoic mark (HEM) visible during administration of the pulse. 13 
The HIFU device calculated the energy and power level of each pulse during treatment. 14 
In this study, only the circumference of the fibroadenoma was ablated; two 15 
circumferential rings were treated and the centre was deselected (figure 1). The Echopulse 16 
device treats only one central, top or bottom disc shaped target volume (curved or 17 
horizontal) during one treatment session. The optimal target volume was selected in order 18 
to avoid thermal damage to skin and pectoral muscle and to cover the most central part 19 
of the fibroadenoma. After the treatment, the patient’s skin was observed for any 20 
treatment related changes. Patients were asked to provide a pain score after the procedure 21 
for pre-, intra- and post-treatment pain using a VAS scoring system between 0 to 10. 22 
Patients followed nurse-led discharge policies in accordance with local protocol. 23 
Circumferential treatment time was recorded from the beginning of the first pulse 24 
to the end of the last pulse, along with the number of pulses delivered. The average time 25 
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to deliver a treatment pulse was calculated (including any delays between pulses due to 1 
prolonged treatment pauses) and used to estimate the total treatment time required to treat 2 
the whole lesion. In addition, total procedure time – including treatment planning and 3 
administration of local anaesthesia - was recorded. 4 
Follow-up  5 
Patients were followed up at two weeks, three, six and 12 months - with a physical 6 
examination and US scan. Clinicians were blinded from the US results during physical 7 
examination but ultra-sonographers performing the scans were not blinded from previous 8 
scan results. The fibroadenoma volume was calculated using standard formulae in which 9 
V is the volume and A, B and C are the maximum diameters measured on US. [11]  10 
V=4/3*π*(1/2 A)*(1/2 B)*(1/2 C) 11 
Statistical analysis  12 
Statistical analysis was performed using IBM SPSS statistics version 23 (SPSS Inc., 13 
Chicago, IL). A paired t-test and Wilcoxon signed rank test were used to determine the 14 
significance of the reduction in fibroadenomata volumes. The logarithms of the initial 15 
and final volumes were calculated and a Pitman-Morgan test was used to determine if the 16 
percentage in volume reduction varies within initial fibroadenomata volumes. An 17 
independent t-test was used to determine of the patients lost to follow-up had different 18 
initial volumes compared to those who completed follow-up and if there was a significant 19 
difference in volume reduction after 12 months between patients with two successfully 20 
treated rings and patients with less than two successfully treated rings. 21 
A Mann-Whitney U-test was used to determine if there were any statistically 22 
significant differences in distribution between the patients with or without post-treatment 23 
hyper-pigmentation in terms of distance of fibroadenomata to the skin, distance of 24 
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fibroadenomata to the pectoralis major muscle, mean power and mean energy used during 1 
the treatment.  2 
Results 3 
Patient screening 4 
A total of 262 patients with fibroadenomata were screened between December 2013 and 5 
September 2015. 46.6% of these patients (122 of 262) were potentially eligible for HIFU 6 
treatment and were approached by our team of which 19.5% (51 of 262) were included 7 
in the trial and treated with HIFU and an additional 20 patients were included in the 8 
HIFU-F trails as control patients (7.6%, 20 of 262). Another 19.5% (51 of 262) were 9 
excluded as they were not contactable or did not want to participate in the trial, 18.3% 10 
(48 of 262) had incidental fibroadenomata, 23.7% (62 of 262) had fibroadenomata smaller 11 
than 1 cm, 3.1% (8 of 262) had giant fibroadenomata and 8.4% (22 of 262) were excluded 12 
due to our exclusion criteria.  13 
Patient characteristics 14 
Circumferential HIFU treatment was performed in 51 patients (53 treatments) with a 15 
mean age of 29.8 years (SD 7.2 years) and a mean fibroadenomata size of 2.6 cm (SD 1.4 16 
cm). The mean distance between the skin and the fibroadenomata was 0.4 cm (SD 0.2 17 
cm) and between the pectoralis major and the fibroadenomata 0.5 cm (SD 0.3 cm). 45.3% 18 
of lesions (24 of 53) were located in the left and 54.7% (29 of 53) in the right breast. 19 
35.8% of lesions (19 of 53) were located in the upper outer quadrant, 18.9% (10 of 53) in 20 
the lower outer quadrant, 28.3% (15 of 53) in the upper inner quadrant and 17.0% (9 of 21 
53) in the lower inner quadrant (table 1a). 22 
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HIFU treatment 1 
Two circumferential rings were completed in 67.9% (36 of 53) of treatments, one ring in 2 
30.2% (16 of 53; only one or two treatment pulses were missing to complete the second 3 
ring in 22.6% (12 of 53)) and in 1.9% (1 of 53) no circumferential ring was completed 4 
and treatment had to be abandoned (table 1b). The central layer was treated in 94.3% (50 5 
of 53) of treatments, the bottom in 3.8% (2 of 53) and the top in 1.9% (1 of 53). 6 
A mean of 16.6 ml (SD 8.3 ml) local anaesthesia was administered prior to the 7 
treatment. HIFU treatment was performed with a mean of 117.2 Joule per pulse (SD 29.6 8 
Joule per pulse; 52 treatments) and 29.1 Watt per pulse (SD 7.3 Watt per pulse; 52 9 
treatments). A mean volume of 0.9 cm3 (SD 0.3 cm3; 52 treatments) was treated during 10 
each treatment session. 11 
Out of 29 patients who were asked if they would have HIFU treatment for 12 
fibroadenomata again, 19 patients replied “yes”, seven patients replied “no” (because of 13 
pain in all cases) and three patients were indecisive. 14 
Treatment times 15 
The mean procedural circumferential treatment time was 32.9 minutes (SD 9.8 minutes). 16 
Circumferential ablation shortened the estimated procedural treatment time by 19.9 17 
minutes (SD 25.1 minutes), which is a mean reduction of 29.4% (SD 15.2%) compared 18 
to whole lesion ablation. Total procedure time – including treatment planning and 19 
administration of local anaesthesia - was 66.0 minutes (SD 16.5 minutes). 20 
Response to treatment 21 
Prior to HIFU treatment the mean fibroadenoma volume was 6.1 cm3 (SD 12.1 cm3). At 22 
two weeks (49 patients (n)) the fibroadenomata showed a slight decrease in volume of 23 
12.3% (SD 27.1%; paired t-test p=0.007; Wilcoxon signed ranks test Z=-2.91, p=0.004) 24 
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to 5.7 cm3 (SD 11.0 cm3). At three months (n=48) the decrease was 14.3% (SD 124.4%; 1 
p=0.002; Z=-3.87, p<0.005) to 3.5 cm3 (SD 4.6 cm3). At six months (n=42) a reduction 2 
of 35.0% (SD 102.8%; p<0.005; Z= -4.47, p<0.005) to 2.8 cm3 (SD 4.3 cm3) was seen. 3 
At 12 months (n= 40) a reduction in volume of 43.2% (SD 35.4%; p<0.005; Z=-4.65, 4 
p<0.005) to 3.0 cm3 (SD 5.3 cm3) was seen (figure 2+3, table 1).  5 
A Pitman-Morgan test showed that large fibroadenomata do not decrease by as 6 
large a percentage of volume as small fibroadenomata (figure 4). In addition, comparing 7 
the patients who completed follow-up with those who were lost to follow-up, it was seen 8 
that there was no statistical difference in initial fibroadenomata volume (independent t-9 
test, unequal variances, t(18)=0.282, p=0.781). No significant difference was seen 10 
between the reductions in fibroadenomata volumes after 12 months for patients with one 11 
or two treatment rings treated (independent t-test, unequal variances, t(26)=0.152, 12 
p=0.880). 13 
All patients were able to feel their fibroadenoma prior to treatment. A total of 14 
24.5% of patients (13 of 53) could no longer feel the fibroadenoma after treatment, in 15 
11.3% (6 of 53) this data was not available and 64.2% (34 of 53) were still able to feel a 16 
residual lump – although reduced in size. An increase in volume was seen in nine patients 17 
at 12 months follow-up. A total of three patients decided to undergo surgery after follow-18 
up (figure 5) due to a lack of response on US. On histopathology, residual fibroadenoma 19 
tissue was seen with areas of fibrosis and fat necrosis. 20 
Pain symptoms 21 
During treatment, the maximum pain felt by patients scored 7.1 (SD 2.6) on a 0-10 VAS 22 
score. If the application of a sonication was paused due to pain, the sonication and 23 
treatment were only completed with consent of the patient. In the single abandoned 24 
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treatment consent to continue treatment was not given. Immediately after treatment pain 1 
was scored 1.6 (SD 1.8). 2 
Pre-treatment a total of 21 patients had pain at the site of the fibroadenoma (VAS 3 
score 1.5 (SD 2.7)). Two weeks post-treatment, 11 patients no longer experienced any 4 
pain and two patients developed pain from the area of the fibroadenoma. At three months 5 
pain was reduced in 15 patients, one patient had recurrent pain, an additional two patients 6 
developed pain and one of two patients who developed pain at two weeks follow-up no 7 
longer felt any discomfort. At six months, 15 patients were pain free, the patient with 8 
recurrent discomfort still had pain near the FAD and all but one patient who developed 9 
pain post-treatment were now pain free. At 12 months, 14 patients with pre-treatment 10 
pain were pain free, all but one patient who developed post-treatment pain were now pain 11 
free and the patient with recurrent discomfort still had pain near the FAD.  12 
Local complications 13 
At two weeks post-treatment, bruising of the skin (n=15 patients), skin erythema (n=12), 14 
skin numbness (n=3) and single cases of hypo-pigmentation, hyper-pigmentation, skin 15 
burns, skin blisters, skin dimpling and pain in the ipsilateral axilla were reported. At three 16 
months post-treatment only one case of skin erythema persisted and at 12 months one 17 
case of skin numbness persisted.  18 
Skin hyper-pigmentation was observed in nine and six cases at three and 12 19 
months respectively (figure 6). There was no significant difference between the distance 20 
from the fibroadenoma to the skin and pectoralis major and the occurrence of hyper-21 
pigmentation (p=0.748 and p=0.969, respectively). No significant difference was 22 
identified between mean power and energy levels used during the treatments and the 23 
occurrence of hyper-pigmentation (p=0.461 and p=0.511, respectively). 24 
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Discussion 1 
Our study has shown that with circumferential HIFU treatment, a treatment time 2 
reduction of 29.4% (SD 15.2%, 32.9 minutes (SD 9.8 minutes)) and a fibroadenoma 3 
volume reduction of 43.2% (SD 35.4%) after 12 months was achieved. The combination 4 
of circumferential treatment and performing this treatment under local anaesthesia 5 
resulted in a treatment, which reduced the fibroadenoma volume but did not make the 6 
lump non-palpable in the majority patients (64.2%; 34 of 53).  7 
This study is the largest cohort of patients with benign breast lesions treated with 8 
HIFU. Circumferential HIFU treatment showed a mean volume reduction of 43.2% (SD 9 
35.4%) after 12 months, an improvement compared to the 35.0% (SD 102.8%) reduction 10 
seen at six months, suggesting that the treatment effect continues up to 12 months post-11 
treatment. Recently, several trials have been published treating fibroadenomata. 12 
Kovatcheva et al. [12] published on 42 women with 51 fibroadenomata who underwent 13 
whole lesion ablation using US guided HIFU and found a 72.5% reduction in volume 14 
after 12 months follow-up. The mean treatment time was 118 minutes and at 12 months, 15 
only one patient with asymptomatic subcutaneous induration was seen. Cavallo 16 
Marincola et al. [13] performed whole lesion US guided HIFU on ten patients and showed 17 
a 50% reduction after three months follow-up and no adverse events. The mean treatment 18 
time from first to last pulse was 57.2 minutes and the mean procedure time was 136 19 
minutes. These studies suggest that whole lesion ablation might be more effective than 20 
circumferential ablation but there are no comparative studies. 21 
Treatment times were reduced by 29.4% and the total amount of time the patient 22 
spent in the treatment room (procedure time) was just over an hour. This treatment 23 
duration is more acceptable to patients than the one to three hour treatment times 24 
described for whole tumour ablation, traditionally seen [8, 9].  25 
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Circumferential HIFU treatment showed a mean volume reduction of 43.2% (SD 1 
35.4%) after 12 months, an improvement compared to the 35.0% (SD 102.8%) reduction 2 
seen at six months, suggesting that the treatment effect continues up to 12 months post-3 
treatment. Volume reduction may have plateaued due to the reduced amount of necrosis 4 
after treatment compared to whole lesion ablation. The epicentre of the fibroadenoma 5 
might not have been necrosed completely as the treatment was unsuccessful in treating 6 
the centre. The Circumferential HIFU treatment aims to cut off the blood supply and if 7 
this is not successful, the reduction might not be as significant as expected. An increase 8 
in volume was seen in 15 patients at two weeks, which can be explained by inflammation 9 
and oedema causing difficulty in determining the size of the fibroadenoma. An increase 10 
in volume was seen in nine patients at 12 months, which might be due to an incomplete 11 
ablation of two circumferential rings. In some patients, an increase of over 100% was 12 
seen which reduced to a decrease or milder increase in volume at the next follow-up. This 13 
might be as a result of unclear borders caused by defragmentation of the fibroadenoma, 14 
leading to an over-estimation of the size. Due to this difference in response to treatment, 15 
patient selection is very important. Patients should be made aware of this gradual decrease 16 
in volume compared to the instant and complete removal of the lesion with surgical 17 
excision. Patients might otherwise become anxious about the persistence of a lesion. 18 
In our study, 13 patients were lost to follow-up, 3.9% (2 of 53) due to surgical 19 
excision of the FAD prior to end of follow-up and 21.6% (11 of 53) were no longer 20 
contactable for the study. Ou et al. [14] performed a study on the lost to follow-up 21 
numbers in high level evidence based studies related to benign prostatic enlargement and 22 
included 41 studies. After 12 months an average lost to follow-up of 12% was found in 23 
39 studies. Our numbers are higher than reported in this study reflecting higher lost to 24 
follow-up rates in patients with benign breast disease. 25 
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HIFU treatment does seem particularly effective for pain management as only 1 
three out of 21 patients with pre-treatment pain still felt pain from the area of the lump 2 
after 12 months. This could be due to treatment pulses being administered to local sensory 3 
pain receptors, hence why locations where patients initially had pain were no longer 4 
painful following subsequent treatment pulses. Patients who presented with pre- or inter- 5 
treatment pain however would like to have the treatment again if they found another 6 
fibroadenoma.  7 
The most common local complication found during this trial was altered skin 8 
pigmentation. In some cases, the altered pigmentation was not noticeable by the patients; 9 
but nevertheless this is a complication, which was reported more often within our study 10 
than any other studies. This might be due to a higher level of cosmesis expected by the 11 
reviewing clinicians. The patients included had fibroadenomata closely located to the skin 12 
and this might be a cause for the hyperpigmentation due to the skin being heated more 13 
than initially expected even though the skin was cooled by the treatment probe. However, 14 
no correlation could be found between the location of the fibroadenoma to the skin, 15 
location of the fibroadenoma to the pectoralis major muscle, energy level used during 16 
treatment and power level used during treatment and the incidence of skin hyper-17 
pigmentation. Neither was a darker pigmented skin a risk factor for altered pigmentation 18 
due to HIFU treatment. 19 
Our study adds to the existing published evidence confirming that HIFU is a 20 
viable alternative option for the treatment of fibroadenomata. Further clinical 21 
implementation and cost-effectiveness analysis is required. Also, aesthetic outcome in 22 
management of symptomatic fibroadenomata is very important in younger women. 23 
Therefore, patient reported outcome measures (PROMS) should also be considered in 24 
order to evaluate aesthetic benefits for patients. 25 
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The initial aim was to recruit 50 control patients in order to compare volume 1 
reduction within the HIFU group with the control group. However, initial assessment of 2 
20 HIFU patients versus 20 control patients showed a statistically significant difference 3 
(p=0.002, grouped t-test) between these two groups after six months, and therefore it was 4 
decided to stop recruitment of the control group. [10] 5 
The immediate, future research evaluation of HIFU would be progression to the 6 
treatment of small (with a diameter of 1 to 3 cm), good prognostic, screen-detected breast 7 
cancers which should aim to demonstrate consistent and complete pathological ablation. 8 
These could be feasibly treated in short timeframes under local anaesthetic. The HIFU 9 
system could also potentially allow US-guided axillary management of suspicious nodes 10 
- in keeping with the emergence of increasing axillary conservatism. This application will 11 
be bolstered by continual technological advancements from manufacturers to enhance 12 
resolution and allow multiple treatment sites during the procedure. However, the first step 13 
should be the standardisation of HIFU treatment for fibroadenomata in the clinical setting 14 
before breast cancer treatment is evaluated within clinical studies.  15 
Conclusion 16 
Circumferential HIFU treatment for breast fibroadenomata is feasible to reduce both 17 
lesion size and treatment time. HIFU is a non-invasive alternative technique for the 18 
treatment of breast fibroadenomata and required further evaluation. 19 
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Table 1. a) Patient and b) HIFU treatment characteristics (SD: standard deviation). 1 
Table 2. Fibroadenomata volumes over time measured with ultrasound (mean (standard 2 
deviation)). 3 
Figure 1. HIFU treatment planning showing the two circumferential treatment rings 4 
(green) and the deselected centre of the fibroadenoma (grey). 5 
Figure 2. Change in fibroadenomata volume on ultrasound over time by patient (n) in 6 
percentage reduction. 7 
Figure 3. Ultrasound images of three patients showing change in volume over time; pre-8 
treatment (a-c), two weeks (d-f), three months (g-i), six months (j-l) and 12 months (m-9 
o) follow-up. 10 
Figure 4. Boxplot of the logarithm of the fibroadenoma volume as seen on ultrasound at 11 
each follow-up moment (1: pre-treatment, 2: two weeks, 3: three months, 4: six months 12 
and 5: 12 months follow-up, °: outliers). 13 
Figure 5. Ultrasound images (pre-treatment - 22*12*12 mm, two week follow-up - 14 
19*8*10 mm and three months follow-up - 19*8*10 mm) showing no change in volume 15 
and histopathology outcome of a patient who underwent surgical excision three months 16 
after HIFU treatment. 17 
Figure 6. Complications recorded during the study (l) skin burn at two weeks and (r) 18 
hyperpigmentation at three months. 19 
